Superior EFS and OS in Patients with Nonmetastatic Osteosarcoma and Unfavourable Prognosis when Adjuvant Mifamurtide is Combined with High-Dose Ifosfamide By Ogkologos - August 28, 2025 267 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the ISG/OS-2 and GEIS-33 studies Source RELATED ARTICLESMORE FROM AUTHOR Treatment with Encorafenib Plus Cetuximab Plus FOLFIRI Improves Outcomes in Patients with BRAF V600E-mutated mCRC FDA Approves Belzutifan with Pembrolizumab for Adjuvant Treatment of Renal Cell Carcinoma How Decades of NCI Support Led to Groundbreaking Discoveries: The Story of Immune Checkpoint Inhibitors MOST POPULAR Failed Alzheimer’s Drug Might Boost CAR T-Cell Therapy for Multiple Myeloma October 25, 2019 The Growths On This Woman’s Lips Are A Sign That She... April 17, 2020 How to Cope With Taking Long-Term Medication June 27, 2023 Survivor Story: Erin June 4, 2021 Load more HOT NEWS How Breast Cancer Risk Assessment Tools Work Holidays, Traditions and Grief EMA Recommends Granting a Marketing Authorisation for Ripretinib for the Treatment... Cancer Won’t Wait: “I prayed she would see her daughter start...
